Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7712887 | 0.74 | ALDH1A1 (0.46) | LMNA | |
| SCHEMBL4334239 | 0.74 | MGAM (0.35) | LMNA | |
| SCHEMBL23462145 | 0.74 | LMNA (0.41) | LMNA | |
| SCHEMBL6535248 | 0.74 | LMNA (0.55) | LMNA | |
| SCHEMBL1171491 | 0.73 | LMNA (0.40) | LMNA | |
| SCHEMBL1171794 | 0.73 | LMNA (0.53) | LMNA | |
| SCHEMBL2865042 | 0.73 | — | — | |
| SCHEMBL3087491 | 0.72 | LMNA (0.39) | LMNA | |
| SCHEMBL6724769 | 0.71 | TSHR (0.35) | — | |
| SCHEMBL8830941 | 0.71 | KDM4E (0.34) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390370-B1 | METHODS FOR PREPARATION OF CYTOTOXIC CONJUGATES OF MAYTANSINOIDS AND CELL BINDING AGENTS | IMMUNOGEN INC (US) | 2016-04-13 | — | — | EP | claimed |
| EP-1390370-A4 | METHODS FOR PREPARATION OF CYTOTOXIC CONJUGATES OF MAYTANSINOIDS AND CELL BINDING AGENTS | IMMUNOGEN INC (US) | 2005-07-06 | — | — | EP | claimed |
| EP-1390370-A1 | METHODS FOR PREPARATION OF CYTOTOXIC CONJUGATES OF MAYTANSINOIDS AND CELL BINDING AGENTS | Immunogen, Inc. (US) | 2004-02-25 | — | — | EP | claimed |
| US-20030055226-A1 | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents | IMMUNOGEN, INC. | 2003-03-20 | — | — | US | claimed |
| WO-2002098883-A1 | METHODS FOR PREPARATION OF CYTOTOXIC CONJUGATES OF MAYTANSINOIDS AND CELL BINDING AGENTS | IMMUNOGEN, INC. (US) | 2002-12-12 | — | — | WO | claimed |
| US-6441163-B1 | COUPLING MAYTANSINOIDS HAVING DISULFIDE LINKER BEARING REACTIVE MOIETY TO SUCH AS ANTIBODIES WITHOUT PRIOR MODIFICATION OF SAID ANTIBODY; ONE-STEP, HIGH YIELD, LOWER COST | IMMUNOGEN, INC. | 2002-08-27 | — | — | US | claimed |
| EP-1390370-B1 | METHODS FOR PREPARATION OF CYTOTOXIC CONJUGATES OF MAYTANSINOIDS AND CELL BINDING AGENTS | IMMUNOGEN INC (US) | 2016-04-13 | — | — | EP | disclosed |
| EP-2348024-B1 | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents | IMMUNOGEN INC (US) | 2015-07-29 | — | — | EP | disclosed |
| EP-2348024-A2 | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents | ImmunoGen, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| US-7368565-B2 | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents | IMMUNOGEN INC. (US) | 2008-05-06 | — | — | US | disclosed |
| EP-1390370-A4 | METHODS FOR PREPARATION OF CYTOTOXIC CONJUGATES OF MAYTANSINOIDS AND CELL BINDING AGENTS | IMMUNOGEN INC (US) | 2005-07-06 | — | — | EP | disclosed |
| EP-1390370-A1 | METHODS FOR PREPARATION OF CYTOTOXIC CONJUGATES OF MAYTANSINOIDS AND CELL BINDING AGENTS | Immunogen, Inc. (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20030055226-A1 | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents | IMMUNOGEN, INC. | 2003-03-20 | — | — | US | disclosed |
| WO-2002098883-A1 | METHODS FOR PREPARATION OF CYTOTOXIC CONJUGATES OF MAYTANSINOIDS AND CELL BINDING AGENTS | IMMUNOGEN, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
| US-6441163-B1 | COUPLING MAYTANSINOIDS HAVING DISULFIDE LINKER BEARING REACTIVE MOIETY TO SUCH AS ANTIBODIES WITHOUT PRIOR MODIFICATION OF SAID ANTIBODY; ONE-STEP, HIGH YIELD, LOWER COST | IMMUNOGEN, INC. | 2002-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055226-A1 | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents | SPR, SELPLG, CD2BP2 | LMNA 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.